Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795–808 (2020).

Article  PubMed  Google Scholar 

The Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273–1285 (2023).

Article  Google Scholar 

Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937–952 (2004).

Article  PubMed  Google Scholar 

Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).

Article  PubMed  Google Scholar 

Cholesterol Treatment Trialists’ Consortium. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).

Article  Google Scholar 

Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527–1535 (2003).

Article  Google Scholar 

Marcus, M. E. et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob. Health 10, e369–e379 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nelson, A. J. et al. Use of lipid, blood pressure, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw. Open 5, e2148030 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378, 1231–1243 (2011).

Article  PubMed  Google Scholar 

Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions: World Health Organization–Wellcome Trust meeting report, 1–3 August 2001. World Health Organization https://apps.who.int/iris/handle/10665/42567 (2002).

Joseph, P. et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 398, 1133–1146 (2021).

Article  CAS  PubMed  Google Scholar 

Castellano, J. M. Polypill strategy in secondary cardiovascular prevention. N. Engl. J. Med. https://doi.org/10.1056/nejmoa2208275 (2022).

Bahiru, E. et al. Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd009868.pub3 (2017).

Cates, et al. Fixed‐dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst. Rev. CD009868 https://doi.org/10.1002/14651858.cd009868.pub2 (2014).

Zamorano, J. et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr. Med. Res. Opin. 27, 821–833 (2011).

Article  PubMed  Google Scholar 

Neutel, J. M. et al. The use of a single‐pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo‐controlled, multicenter study. J. Clin. Hypertens. 11, 22–30 (2009).

Article  CAS  Google Scholar 

Castellano, J. M. et al. A polypill strategy to improve adherence results from the FOCUS project. J. Am. Coll. Cardiol. 64, 2071–2082 (2014).

Article  PubMed  Google Scholar 

Selak, V. et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Br. Med. J. 348, g3318 (2014).

Article  Google Scholar 

Patel, A. et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur. J. Prev. Cardiol. 22, 920–930 (2014).

Article  PubMed  Google Scholar 

Malekzadeh, F. et al. A pilot double‐blind randomised placebo‐controlled trial of the effects of fixed‐dose combination therapy (‘polypill’) on cardiovascular risk factors. Int. J. Clin. Pr. 64, 1220–1227 (2010).

Article  CAS  Google Scholar 

Park, J.-S. et al. Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des. Dev. Ther. 10, 2599–2609 (2016).

Article  CAS  Google Scholar 

PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘polypill’) in people with raised cardiovascular risk. PLoS ONE 6, e19857 (2011).

Article  PubMed Central  Google Scholar 

Soliman, E. Z. et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials https://doi.org/10.1186/1745-6215-12-3 (2011).

The Indian Polycap Study (TIPS). Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373, 1341–1351 (2009).

Grimm, R. et al. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc. Health Risk Manag. 6, 261–271 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).

Article  CAS  PubMed  Google Scholar 

Wald, D. S., Morris, J. K. & Wald, N. J. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE 7, e41297 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, S.-H. et al. Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter phase III study. Clin. Ther. 38, 2171–2184 (2016).

Article  CAS  PubMed  Google Scholar 

Oh, G. C. et al. Efficacy and safety of fixed-dose combination therapy with telmisartan and rosuvastatin in Korean patients with hypertension and dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a multicenter, randomized, 4-arm, double-blind, placebo-controlled, phase III study. Clin. Ther. 40, 676–691.e1 (2018).

Article  CAS  PubMed  Google Scholar 

Cho, K. I. et al. Efficacy and safety of a fixed-dose combination of candesartan and rosuvastatin on blood pressure and cholesterol in patients with hypertension and hypercholesterolemia: a multicenter, randomized, double-blind, parallel phase III clinical study. Clin. Ther. 41, 1508–1521 (2019).

Article  CAS  PubMed  Google Scholar 

Muñoz, D. et al. Polypill for cardiovascular disease prevention in an underserved population. N. Engl. J. Med. 381, 1114–1123 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Roshandel, G. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672–683 (2019).

Article  CAS  PubMed  Google Scholar 

Chung, S. et al. Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: the randomized FIXAR study. Cardiol. J. 29, 815–823 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Mariani, J. et al. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Ther. Adv. Cardiovasc. Dis. 14, 1753944720912071 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi, J. et al. Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: a pilot study. J. Clin. Hypertens. 23, 1664–1674 (2021).

Article  Google Scholar 

González-Juanatey, J. R. et al. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev. Esp. Cardiol. Engl. Ed. 74, 51–58 (2021).

Article  PubMed  Google Scholar 

Yusuf, S. et al. Polypill with or without aspirin in persons without cardiovascular disease. N. Engl. J. Med. 3, 216–228 (2021).

Article  Google Scholar 

Merat, S. et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur. Heart J. 21, 2023–2033 (2022).

Article  Google Scholar 

Kim, W. et al. A randomized, double‐blind clinical trial to evaluate the efficacy and safety of a fixed‐dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. J. Clin. Hypertens. 22, 261–269 (2020).

Article  CAS  Google Scholar 

Zhu, J. Z. et al. Medication use for cardiovascular disease prevention in 40 low- and middle-income countries. J. Am. Coll. Cardiol. 81, 620–622 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Yusuf, S. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. 374, 2032–2043 (2016).

Article  CAS  PubMed  Google Scholar 

Jahangiri, R. et al. Cost-effectiveness of fixed-dose combination pill (polypill) in primary and secondary prevention of cardiovascular disease: a systematic literature review. PLoS ONE 17, e0271908 (2022).

Article  CAS